Advertisement

Topics

Merck confirms full-year guidance despite headwinds

07:11 EST 9 Nov 2017 | Bionity

Merck reported third-quarter Group sales at the year-earlier level. EBITDA pre exceptionals decreased by -8.3% owing to higher spending on research and development, preparations for the market launches in Healthcare, as well as the business performance of Liquid Crystals. “We generated healthy organ...

Original Article: Merck confirms full-year guidance despite headwinds

NEXT ARTICLE

More From BioPortfolio on "Merck confirms full-year guidance despite headwinds"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...